Myriad Genetics AI Price Prediction

Myriad Genetics is currently unprofitable, as reflected in its negative EPS and negative P/E ratio. The valuation metric (P/E of -56.24) suggests investors are paying a high price relative to current losses, implying expectations for a turnaround that has yet to materialize. Without evidence of improving margins or a clear path to sustained profitability, the financial profile remains weak.

• Negative EPS of -0.11 indicates the company is loss-making rather than generating net income.
• A P/E ratio of -56.24 underscores that the stock is being valued despite ongoing losses, which heightens execution and turnaround risk.
• Lack of visible profitability pressures key ratios such as net margin and return on equity, pointing to an overall challenged financial performance until earnings improve.

The stock has declined 16% over the last month and trades far below its 200-day moving average, signaling a pronounced downtrend. An RSI of 45.23 is neutral to slightly weak, indicating neither oversold capitulation nor strong buying momentum. Overall, price action and long-term technicals lean clearly negative.

• Current price of $6.13 is dramatically below the 200-day moving average of $20.78, reflecting a sustained long-term downtrend and prior significant drawdown.
• A 16% decline over the past month points to recent selling pressure and weak near-term sentiment.
• RSI at 45.23 is below the 50 midpoint, suggesting mildly bearish momentum without reaching oversold levels that might signal an imminent technical rebound.

Myriad Genetics currently presents a challenging investment profile, with unprofitable operations, a negative P/E, and a stock price deeply below its long-term moving average. Alternative data is broadly stable rather than improving, offering little evidence of near-term demand acceleration or renewed investor enthusiasm. Overall, the balance of evidence points to a bearish outlook until there is clear progress on profitability and a reversal in price momentum.

• Unprofitable financials and a deeply discounted price versus the 200-day moving average signal elevated risk and weak market confidence.
• Flat to slightly mixed alternative data (web traffic and social metrics) does not yet support a strong turnaround or growth narrative.